Last mentioned: Mar 6, 2026
Earnings Release
Companies report Q4 and Full Year 2025 results, signaling a shift to 2026 commercial targets.
Fiscal Year End
Med-tech firms report record system utilization rates for the 2025 calendar year.
Clinical Enrollment
Atea Pharmaceuticals completes enrollment for the Phase 2 Hepatitis C (HCV) trial.
Reimbursement Milestone
Profound Medical receives expanded CPT code coverage for TULSA-PRO in the U.S.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a critical transition period as they navigate commercial launches and reimbursement hurdles. While both firms faced revenue headwinds, Kura's $7 billion AML opportunity and Profound's significant EPS beat underscore a shifting landscape in oncology and incision-less surgery.
Atea Pharmaceuticals and Profound Medical headlined a series of Q4 2025 earnings reports, highlighting a shift toward commercial scaling in medical devices and late-stage clinical milestones in biotech. These results underscore a sector-wide focus on capital preservation and high-margin recurring revenue models.
This page surfaces every story mentioning Profound Medical across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Profound Medical was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |